Presentation is loading. Please wait.

Presentation is loading. Please wait.

Serum osteopontin (sOPN) and C reactive protein (CRP) in patients with giant cell arteritis (GCA) in remission according to treatment. (A) sOPN in patients.

Published byBerto Boscolo Modified over 5 years ago

Similar presentations

Presentation on theme: "Serum osteopontin (sOPN) and C reactive protein (CRP) in patients with giant cell arteritis (GCA) in remission according to treatment. (A) sOPN in patients."— Presentation transcript:

1 Serum osteopontin (sOPN) and C reactive protein (CRP) in patients with giant cell arteritis (GCA) in remission according to treatment. (A) sOPN in patients with GCA in remission with high-dose prednisone (PDN) (≥20 mg/day), low-dose prednisone (≤10 mg/day) or with tocilizumab (TCZ). Serum osteopontin (sOPN) and C reactive protein (CRP) in patients with giant cell arteritis (GCA) in remission according to treatment. (A) sOPN in patients with GCA in remission with high-dose prednisone (PDN) (≥20 mg/day), low-dose prednisone (≤10 mg/day) or with tocilizumab (TCZ). (B) Serum CRP concentration in patients with GCA in remission with high-dose prednisone (≥20 mg/day), low-dose prednisone (≤10 mg/day) or with TCZ. **p=0.017 vs high-dose prednisone group and p<0.001 vs low-dose prednisone group. Sensitivities (minimal detectable concentration) of OPN and CRP immunoassay are 0.011 ng/mL and 0.010 ng/mL, respectively. Sergio Prieto-González et al. RMD Open 2017;3:e000570 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Serum osteopontin (sOPN) and C reactive protein (CRP) in patients with giant cell arteritis (GCA) in remission according to treatment. (A) sOPN in patients."

Similar presentations

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.
Changes in PMR-AS, CRP levels, and GC dosage (prednisone) following TCZ therapy in 7 patients with PMR. Since our series included patients with long duration.

Changes in PMR-AS, CRP levels, and GC dosage (prednisone) following TCZ therapy in 7 patients with PMR. Since our series included patients with long duration.
Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.

Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.
Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.
Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)
Changes in evaluation indicators from baseline to 12 weeks per visit.

Changes in evaluation indicators from baseline to 12 weeks per visit.
Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.
Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.
Odds ratios for achieving ACR50 response, ACR70 response, DAS28-CRP LDA, DAS28-CRP remission and CDAI LDA at weeks 12 and 24. High, >median value in overall.

Odds ratios for achieving ACR50 response, ACR70 response, DAS28-CRP LDA, DAS28-CRP remission and CDAI LDA at weeks 12 and 24. High, >median value in overall.
VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.

VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.
P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.

P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.

Similar presentations

Ads by Google